Paper

The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.

Published Dec 1, 2018 · K. Cox, M. Nyilas, P. Perry

Journal of affective disorders

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

RCT

Rigorous Journal

Study Snapshot

Aripiprazole once-monthly 400 mg is a well-tolerated maintenance treatment for bipolar I disorder, with minimal adverse events and minimal weight gain.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.

References

Citations